In HR+/HER2- cancers, EDSA-BC SE was 100% and compared well to 81.8% and 80-100% for Signatera (n = 18/22) and Guardant Reveal (n = 8/10, 8/8), respectively (Table S6) [50,65,66]. This evidence concerns the gene ERBB2 and breast cancer.